XT
PLX icon

XTX Topco’s Protalix BioTherapeutics PLX Stock Holding History

XTX Topco’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,296
Closed -$61.7K – 4249
2025
Q4 		$61.7K Sell
34,296
-51,545
-60% -$105K ﹤0.01% 2784
2025
Q3 		$191K Buy
85,841
+12,166
+17% +$19.8K 0.01% 1866
2025
Q2 		$109K Buy
73,675
+31,849
+76% +$65.2K ﹤0.01% 1867
2025
Q1 		$107K Buy
+41,826
New +$99.9K 0.01% 1856
2024
Q4 		– Sell
-35,058
Closed -$35.8K – 2788
2024
Q3 		$35.8K Buy
+35,058
New +$36.9K ﹤0.01% 1752
2024
Q1 		– Sell
-18,750
Closed -$33.4K – 2211
2023
Q4 		$33.4K Sell
18,750
-65,223
-78% -$101K 0.01% 1296
2023
Q3 		$139K Sell
83,973
-86,905
-51% -$156K 0.02% 1124
2023
Q2 		$342K Buy
170,878
+136,814
+402% +$326K 0.06% 622
2023
Q1 		$71.5K Buy
+34,064
New +$59.8K 0.02% 1132
2021
Q4 		– Sell
-20,514
Closed -$27K – 935
2021
Q3 		$27K Buy
20,514
+3,366
+20% +$5.12K 0.01% 633
2021
Q2 		$33K Buy
+17,148
New +$59K 0.01% 747

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

XTX Topco's PLX Position: Q1 2026 in Review

XTX Topco sold out of Protalix BioTherapeutics (PLX) in Q1 2026, closing a stake of 34,296 shares — an estimated $61.7K sold.

XTX Topco first reported a position in PLX in Q2 2021 and held it in 11 quarters. The position peaked at $342K in Q2 2023. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • XTX Topco reported no remaining Protalix BioTherapeutics position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 34,296 Protalix BioTherapeutics shares in Q1 2026, an estimated $61.7K.
  • XTX Topco first reported a position in Protalix BioTherapeutics in Q2 2021 and held it in 11 quarters.
  • XTX Topco's Protalix BioTherapeutics position peaked at $342K in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.